skip to main content

S. 2842: Opioid Addiction Recovery Fraud Prevention Act of 2018

A bill to prohibit the marketing of bogus opioid treatment programs or products.

The bill’s titles are written by its sponsor.

Sponsor and status

Shelley Capito

Sponsor. Junior Senator for West Virginia. Republican.

Read Text »
Last Updated: May 15, 2018
Length: 7 pages
Introduced:

May 15, 2018

Status:

Ordered Reported on May 22, 2018

The committees assigned to this bill sent it to the House or Senate as a whole for consideration on May 22, 2018.

Prognosis:

25% chance of being enacted according to Skopos Labs (details)

History

May 15, 2018
 
Introduced

Bills and resolutions are referred to committees which debate the bill before possibly sending it on to the whole chamber.

May 22, 2018
 
Ordered Reported

A committee has voted to issue a report to the full chamber recommending that the bill be considered further. Only about 1 in 4 bills are reported out of committee.

Pending
 
Passed Senate (House next)

Pending
 
Passed House

Pending
 
Signed by the President

S. 2842 is a bill in the United States Congress.

A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.

How to cite this information.

We recommend the following MLA-formatted citation when using the information you see here in academic work:

“S. 2842 — 115th Congress: Opioid Addiction Recovery Fraud Prevention Act of 2018.” www.GovTrack.us. 2018. June 19, 2018 <https://www.govtrack.us/congress/bills/115/s2842>

Where is this information from?

GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.